Michelle L. E. Peake
Director/Board Member at VIROPRO INC.
Profile
Michelle L.
E.
Peake is currently the Director at Viropro, Inc. since 2012 and the Chief Operating Officer at Alpha Biologics Ltd.
since 2009.
Previously, she was the Chief Executive Officer at Alpha Biologics Sdn.
Bhd.
in 2011.
Ms. Peake completed her undergraduate degree at Griffith University in 1993.
Michelle L. E. Peake active positions
Companies | Position | Start |
---|---|---|
VIROPRO INC. | Director/Board Member | 19/10/2012 |
Alpha Biologics Ltd.
Alpha Biologics Ltd. Pharmaceuticals: MajorHealth Technology Alpha Biologics is a Contract Manufacturer of Biologics drugs for use in pre-clinical, Phase1 and 2 clinical trials, anywhere in the World. The life sciences industry is experiencing spiralling drug development costs that are making it increasingly difficult for biotech and pharma companies to survive, let alone prosper. Alpha Biologics has been established to address this issue by providing its clients with the opportunity to take their biologic drugs through the early clinical trial phases at a cost is easily justified. This avoids the abandonment of potential blockbuster drug programmes based simply on cost before it has been possible to demonstrate safety and early efficacy. It specialises in the production of mammalian cell secreted protein drugs, and it provide all of the necessary services required to develop and produce its clients' drugs in full compliance with U.S. and European cGMP guidelines. Its manufacturing base in Malaysia brings significant cost advantages to its customers due to the lower overhead costs compared with Europe or the U.S., whilst maintaining the highest standards of compliance. Its core team has extensive experience of designing, building and operating cGMP compliant facilities for biologic drugs in the U.S. and Europe. This core team has been strengthened by internationally trained and experienced staff from the World-wide biologics industry and academia. Its goal is to deliver drugs on time for clinical trials at a price that is affordable, thereby enabling its clients' to maintain strong drug development pipelines and realise maximum value from the investments in research and development. | Corporate Officer/Principal | - |
Former positions of Michelle L. E. Peake
Companies | Position | End |
---|---|---|
Alpha Biologics Sdn. Bhd.
Alpha Biologics Sdn. Bhd. Pharmaceuticals: MajorHealth Technology Part of Viropro, Inc., Alpha Biologics Sdn. The private company is based in Penang, Malaysia. Bhd. develops pharmaceutical products. Alpha Biologics Sdn. was acquired by Viropro, Inc. from Alpha Biologics Ltd. on July 12, 2011 for $29.76 million. | Chief Executive Officer | - |
Training of Michelle L. E. Peake
Griffith University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
VIROPRO INC. | Health Technology |
Private companies | 2 |
---|---|
Alpha Biologics Sdn. Bhd.
Alpha Biologics Sdn. Bhd. Pharmaceuticals: MajorHealth Technology Part of Viropro, Inc., Alpha Biologics Sdn. The private company is based in Penang, Malaysia. Bhd. develops pharmaceutical products. Alpha Biologics Sdn. was acquired by Viropro, Inc. from Alpha Biologics Ltd. on July 12, 2011 for $29.76 million. | Health Technology |
Alpha Biologics Ltd.
Alpha Biologics Ltd. Pharmaceuticals: MajorHealth Technology Alpha Biologics is a Contract Manufacturer of Biologics drugs for use in pre-clinical, Phase1 and 2 clinical trials, anywhere in the World. The life sciences industry is experiencing spiralling drug development costs that are making it increasingly difficult for biotech and pharma companies to survive, let alone prosper. Alpha Biologics has been established to address this issue by providing its clients with the opportunity to take their biologic drugs through the early clinical trial phases at a cost is easily justified. This avoids the abandonment of potential blockbuster drug programmes based simply on cost before it has been possible to demonstrate safety and early efficacy. It specialises in the production of mammalian cell secreted protein drugs, and it provide all of the necessary services required to develop and produce its clients' drugs in full compliance with U.S. and European cGMP guidelines. Its manufacturing base in Malaysia brings significant cost advantages to its customers due to the lower overhead costs compared with Europe or the U.S., whilst maintaining the highest standards of compliance. Its core team has extensive experience of designing, building and operating cGMP compliant facilities for biologic drugs in the U.S. and Europe. This core team has been strengthened by internationally trained and experienced staff from the World-wide biologics industry and academia. Its goal is to deliver drugs on time for clinical trials at a price that is affordable, thereby enabling its clients' to maintain strong drug development pipelines and realise maximum value from the investments in research and development. | Health Technology |
- Stock Market
- Insiders
- Michelle L. E. Peake